# Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.

> **NCT00422955** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Neuropathy, Diabetic

## Interventions

- **DRUG:** rosiglitazone

## Key facts

- **NCT ID:** NCT00422955
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422955, "Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00422955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*